Pharmaceutical industry sees leadership shifts and FDA approvals

The pharmaceutical industry is seeing significant shifts in market leadership and regulatory milestones. Pharmaceutical Executive’s 2026 Top 50 Companies report highlights Eli Lilly climbing to the number one spot, marking a major change in the industry rankings.

In regulatory news, the FDA has granted accelerated approval to Bristol Myers Squibb’s Zenbexus for the treatment of adults with relapsed or refractory multiple myeloma. Zenbexus is the first approved CELMoD therapy in this category.

In financial markets, several institutional investors have adjusted their positions in major companies. Global Retirement Partners LLC established a new $8.88 million position in Amgen Inc. during the second quarter. Meanwhile, Ameriprise Financial, Inc. saw varied activity, including a 53.5% position increase by Plato Investment Management Ltd and a 36.3% reduction by Janney Montgomery Scott LLC. Additionally, the North Dakota State Investment Board increased its holdings in Bristol Myers Squibb by 29.5%.